Michael Jaramillo, Author at Renibus Therapeutics

Renibus Reports Positive Final Results from Phase 2 Study of RBT-1, a First-in-Class Preconditioning Agent for Patients Undergoing Cardiothoracic Surgery, at the American Association for Thoracic Surgery (AATS) Meeting

Renibus Reports Positive Final Results from Phase 2 Study [...]

Michael Jaramillo2023-05-07T07:54:11-07:00May 5, 2023|

Renibus Therapeutics Announces Presentation at 22nd Annual Needham Virtual [...]

Michael Jaramillo2023-04-05T04:59:52-07:00April 5, 2023|

Renibus Therapeutics Announces Presentation at Oppenheimer 33rd Annual Healthcare [...]

Michael Jaramillo2023-03-07T13:05:09-08:00March 7, 2023|

Renibus Therapeutics Announces Participation in the SVB Securities Global Biopharma [...]

Michael Jaramillo2023-01-30T05:01:59-08:00January 30, 2023|

Renibus Therapeutics Announces Oral Presentation on RBT-1 Phase 2 [...]

Michael Jaramillo2023-01-19T05:01:28-08:00January 19, 2023|

Renibus Therapeutics Announces Positive 30-Day Topline Data from RBT-1 [...]

Michael Jaramillo2023-01-06T12:35:46-08:00January 5, 2023|

Renibus Therapeutics Strengthens Leadership Team with Asha Ramdas as [...]

Michael Jaramillo2022-12-13T05:01:00-08:00December 13, 2022|

Renibus Therapeutics Raises $33 million Bridge Financing to Advance [...]

Michael Jaramillo2022-11-13T21:20:28-08:00November 14, 2022|

Renibus Therapeutics Presents Interim Phase 2 Data: RBT-1 Improves [...]

Michael Jaramillo2022-11-07T12:12:44-08:00November 7, 2022|

Michael Jaramillo2022-10-15T15:56:08-07:00October 5, 2022|